For decades, the idea that you could read what a person is thinking from how their eyes move has lived almost entirely inside university labs: a source of research papers, expensive rigs, and very little anyone could buy. SOMAREALITY, a Vienna software company founded in 2020, just raised over €3 million in an oversubscribed Series A to drag that science out of the lab and onto wearable glasses, and the more interesting fact than the raise is that it claims more than €2 million in revenue while doing it.

The science underneath is genuine and old. The eye does not move smoothly; it jumps between fixation points in flicks called saccades, hundreds of times a minute, almost all of them beneath conscious notice. Decades of research have established that the pattern of those jumps and pauses encodes things the rest of you would rather keep private: how hard you are concentrating, where your attention actually is, how tired you have become. SOMAREALITY’s claim is that a few seconds of this data, captured by a camera small enough to sit in eyewear, is enough to read cognitive load, attention and fatigue in real time. The hard part was never the theory. It was making it work outside a controlled rig, on a moving human, cheaply enough to sell.

The capital is staying in the region, which is its own story

The round was led by Catalyst Romania, with existing backers MT-Lab, RDY Ventures, Moondust Ventures and Gateway Ventures following on. For Catalyst the deal is its thirteenth investment from its second fund and its third bet in Central and Eastern Europe outside Romania, the kind of detail that says quietly that Central European venture capital is staying in Central Europe rather than chasing its best companies to Berlin or London. The money funds three declared priorities: deepening the existing business-to-business work, supporting newly launched longitudinal studies, and building the risky one, a consumer brand that would put cognitive read-outs in the hands of ordinary people.

That third priority is where the skeptic should sit up straight. Consumer neuro-wellness is a graveyard. It is littered with apps and headbands that promised to quantify your brain and delivered a soothing coloured chart and a churned subscription three months later. The leap from selling a rigorous instrument to a professional buyer, who values the science and tolerates the friction, to selling an insight to a consumer, who wants a number and a dopamine hit, is exactly where this category goes to die. Co-founder Adrian Brodesser frames the move as a natural extension: having proven the science in B2B, the company wants to reach “anyone who has always wanted to understand how their mind works but has never been able to outside of the lab.” The ambition is clear. So is the cliff.

The thing that makes this not just another brain app

Here is what separates SOMAREALITY from the wellness graveyard, at least for now: the business is real before the consumer dream. The company reports more than €2 million in B2B revenue since it went to market in 2024, and says that figure more than doubled in 2025, with paying customers in aviation, healthcare and professional sport. Those are not idle buyers. Aviation cares about pilot fatigue because the alternative is a crash. Professional sport cares about attention and cognitive load because marginal gains are the whole industry. Healthcare cares because cognitive monitoring has clinical uses. These customers paid because the measurement told them something they could act on, which is a far harder test than a consumer tapping “buy” on a sleek app.

So the question is not whether the technology works. The revenue and the customer list answer that. The question is whether a tool validated by demanding professional buyers survives contact with the consumer market, where rigor is invisible and the competition is a free app with better marketing. Building a defensible consumer brand on top of proven B2B science is a genuinely different game, and plenty of strong instruments have lost it. What SOMAREALITY has that most brain-app casualties never did is a real revenue line, growing, from customers who had every reason to be skeptical and bought anyway. That is not proof the consumer bet will land. It is proof the science was never the weak part.